E

Edgewise Therapeutics

Develops therapies for rare muscular disorders

Overview

Edgewise Therapeutics develops therapies for rare muscle disorders using a proprietary drug discovery platform. Its lead molecule, sevasemten (EDG 5506), targets the muscle motor protein myosin to reduce stress in fast skeletal muscle fibers, aiming to improve muscle health without affecting other muscle types. The company owns global development and commercialization rights to its programs and pursues strategic collaborations and asset acquisitions to accelerate its pipeline. Its focus is precision medicine for conditions like Duchenne muscular dystrophy, Becker muscular dystrophy, Limb Girdle muscular dystrophies, and McArdle disease. Overall, Edgewise seeks to deliver targeted treatments that protect and improve muscle health for patients and families affected by these rare diseases.

Work here?Claim your company

About Edgewise Therapeutics

Simplify's Rating
Why Edgewise Therapeutics is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Boulder, CO

Founded

2017

Get referred to Edgewise Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • November 4, 2026 management said EDG-7500 Phase 3 remains on track for year-end 2026.
  • August 2026 CIRRUS-HCM data and JCI Insight publication strengthened EDG-7500 differentiation in HCM.
  • November 2026 first-patient dosing in EQUINOX-HFpEF opened a second clinical catalyst beyond HCM.

What critics are saying

  • November 3, 2026 Servier's GRAND CANYON failed both primary and secondary endpoints, hurting validation.
  • EDG-7500 still needs a successful 600-patient Phase 3 starting in fourth quarter 2026.
  • If EDG-7500 disappoints, Edgewise becomes a cash-rich orphan with no revenue and thin pipeline.

What makes Edgewise Therapeutics unique

  • July 2026 transformed Edgewise into a cardiovascular pure play with EDG-7500, EDG-15400, EDG-003.
  • EDG-7500 targets the regulatory light chain, a distinct mechanism versus myosin inhibitors like mavacamten.
  • November 2026 cash reached $1.744 billion, funding EDG-7500 through potential approval.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$925M

Above

Industry Average

Funded Over

7 Rounds

Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • 401(k) Company Match
  • Stock Options
  • Employee Stock Purchase Plan

Stock Price

Growth & Insights and Company News

6 month growth

-9%

1 year growth

0%

2 year growth

42%
MJH Life Sciences
Nov 7th, 2026
The HCM pipeline and moving past beta-blockers, with Ahmad Masri, MD, MS.

The HCM pipeline and moving past beta-blockers, with Ahmad Masri, MD, MS. Ahmad Masri, MD, MS, highlights HCM agents to watch in 2027, including sotagliflozin and EDG-7500, and how MAPLE-HCM challenged beta-blocker use. Beta-blockers have served as initial treatment for symptomatic obstructive (HCM) despite limited evidence of their efficacy.[1] The phase 3 MAPLE-HCM trial randomized 175 adults with symptomatic obstructive HCM to aficamten or metoprolol monotherapy, with results published in The New England Journal of Medicine.[1] At 24 weeks, peak oxygen uptake increased by 1.1 mL/kg/min with aficamten and declined by 1.2 mL/kg/min with metoprolol (difference, 2.3 mL/kg/min; 95% CI, 1.5-3.1; P < .001).[1] Patients receiving aficamten also showed greater improvements in New York Heart Association functional class, Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), left ventricular outflow tract gradient, and N-terminal pro-B-type natriuretic peptide level.[1] Late-stage development in HCM now extends beyond cardiac myosin inhibition. Lexicon Pharmaceuticals completed enrollment in SONATA-HCM, a phase 3 trial of the dual SGLT1 and SGLT2 inhibitor sotagliflozin in nonobstructive and obstructive HCM, with topline results expected in the first quarter of 2027.[2] The trial exceeded its target of 500 patients across more than 130 sites in 20 countries, and its primary end point is change in KCCQ-CSS at week 26.[2] Edgewise Therapeutics plans to start phase 3 development of EDG-7500, a cardiac sarcomere modulator designed to address impaired relaxation, in the fourth quarter of 2026.[3] In the 12-week phase 2 CIRRUS-HCM trial, no patients receiving EDG-7500 had reductions in left ventricular ejection fraction to below 50%.[3] Ahmad Masri, MD, MS, director of the Hypertrophic Cardiomyopathy Center and Cardiac Amyloidosis Program at Oregon Health & Science University, is a coauthor of MAPLE-HCM and principal investigator of ACACIA-HCM. Masri sat down with HCPLive at the American Heart Association Scientific Sessions 2026 in Chicago to discuss the HCM agents to watch in 2027 and how MAPLE-HCM reshaped the evidence base. Q&A: Sotagliflozin, EDG-7500, and the HCM pipeline for 2027. HCPLive: Looking ahead to 2027, which studies, trials, or new agents should the field keep an eye on? Ahmad Masri, MD, MS: It's such an exciting time to think about this, because again, everybody is realizing that there's severe unmet need and HCM is actually a sizable population that you can work with. The sites, the PIs, and the clinicians are now very sophisticated in how they find the patients and how they select them for studies, so part of the work has already been done there, which is really setting up for success. In terms of ongoing trials, Hcplive has a few. You have 2 new phase 3 trials that should come next year. One is with a sarcomere modulator called EDG-7500 that has a different mechanism of action than the CMIs, so that's going to be in a phase 3 trial. Hcplive has a phase 3 trial of a third CMI in class. I don't really like lumping these drugs together. Mavacamten, aficamten, and the third one, BHB-1893 or HRS-1893, all bind to different sites. They have different implications, so I like to treat them as individual drugs, if possible. That's another phase 3 that is also coming to sites. Outside of this, there are actually a few other things that are quite novel in its thinking. One of them is very close to the finish line, which is a combined SGLT1 and SGLT2 inhibitor called sotagliflozin. The study is SONATA-HCM, and it should be reporting out next year. Keep your eye on that, because it's a completely different mechanism from what Hcplive usually do in HCM. Hcplive has a new antifibrotic, and it's not just that it's a new antifibrotic that makes it very exciting. It is actually the first-in-human approach to addressing what's called a long noncoding RNA. It's an RNA medicine by HAYA Therapeutics called HTX-001 that is meant to reduce a certain long noncoding RNA called WISPER. If you downregulate it, you have less fibrosis. So it's hitting 2 things at the same time. One is characterizing this biology for all of medicine when you're addressing a long noncoding RNA, and the other is doing something in HCM that could extend to other disease spaces and hasn't been done, which is: How can you address the big problem of progression of fibrosis in diseases of the heart? Hcplive don't have solutions for that at this stage, so that's another mechanism Hcplive is very excited about. There are a lot of things happening in the early clinical space. Hcplive also have a different mechanism of action on energy modulation. Ninerafaxstat is a drug that shifts how the heart uses energy, maybe allowing it to be smarter in how it works with a disease condition like HCM. Hcplive has a study called FORTITUDE-HCM that is in phase 2b and ongoing as well. So, lots of things happening. HCPLive: How does your optimism about where the cardiomyopathy field is going now compare to where is was 5 years ago? Ahmad Masri, MD, MS: In terms of optimism, Hcplive finally are at a stage where everyone understands the unmet need and understands the why. If you look back 6 or 7 years ago, there was actually hesitancy and suspicion: Why are you developing therapies in HCM? It's a solved problem. [UNCLEAR - please review: "and now you're inching it to"] I think Hcplive has already done that, which is convincing the majority that you need to step away from the traditional thinking and really become more evidence-based, and think about it like how Hcplive think in heart failure with reduced ejection fraction, for example. Show me the data and show me the evidence. I think MAPLE-HCM delivered big on this, where it challenged decades of beta blocker use in hypertrophic cardiomyopathy. It's a courageous trial. You could argue, why would you risk running such a trial? But it delivered for HCM what none of the other trials delivered, not because of efficacy, but because of showing that metoprolol, the primary drug used in all of the United States (outside, they use other beta blockers), is actually harmful to these patients. This is what I see changing: Finally, it is sticking that there is a problem here and that Hcplive has to move away from expert opinions and expert consensus. Hcplive has to actually think about the data and the evidence. Where do Hcplive has areas where Hcplive don't have data and evidence that Hcplive can actually work on and solve as well? I think there is no going back. The last 5 years have been amazing, and I think it's the start of something really great in hypertrophic cardiomyopathy and beyond, because this space now allowed Hcplive to think about cardiomyopathies as individual diseases, not as a group that is a subset of heart failure, which I think is really important. Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Yahoo Finance
Nov 7th, 2026
Edgewise wins FDA alignment on Phase 3 heart drug trial as Q3 net income hits $1.17B

Edgewise Therapeutics held a favourable End-of-Phase 2 meeting with the US Food and Drug Administration (FDA), clearing the way to submit the STRATUS-HCM Phase 3 protocol for EDG-7500, its drug for hypertrophic cardiomyopathy. The trial will use an echo-independent, investigator-guided dose escalation design across obstructive and nonobstructive forms of the disease, under a single global master protocol. It is expected to enrol about 600 patients and start in the fourth quarter of 2026. The company reported Q3 2026 net income of $1,166.15 million, driven by large one-off items tied to portfolio reshaping. It has no material recurring product revenue and a current loss of $197.2 million. Analysts project revenue of $135.6 million and earnings of $22.1 million by 2029.

Himma AI
Nov 5th, 2026
EWTX stock rises 4.3% on Q3 results and EDG-7500 progress.

EWTX stock rises 4.3% on Q3 results and EDG-7500 progress. Edgewise Therapeutics shares rose 4.3% after Q3 results showed a $1.17 billion profit from the sevasemten sale and a Phase 3 EDG-7500 trial on track. Edgewise Therapeutics (EWTX) stock was up 4.3% in regular trading on November 5, 2026, the day after the company reported third quarter results. Cash, cash equivalents and marketable securities reached $1,743.9 million on September 30, 2026, up from $530.1 million at the end of 2025. What edgewise Therapeutics reported. | Metric | This period | A year earlier | Change | | R&D expenses | $31.6M | $37.5M | Down 16% | | G&A expenses | $14.6M | $9.4M | Up 55% | | Interest income | $16.5M | $6.2M | Up 166% | | Net income (loss) | $1,166.2M | ($40.7M) | Swung to profit | | Diluted EPS | $9.65 | ($0.39) | Swung to profit | Diluted EPS is profit per share, counting shares that options and similar awards could add. The profit is a one-off. It comes from a $1.348 billion gain on selling the sevasemten program and muscular dystrophy business to Servier in July 2026, which brought in $1.396 billion of upfront cash. Income tax expense on the deal was $155.3 million. The company still has no revenue from product sales. R&D (research and development) spending fell mainly because sevasemten costs stopped after the sale. Spending on EDG-7500 and early-stage research went up. G&A (general and administrative) costs rose on hiring, stock-based pay and professional fees. Why the stock rose 4.3%. The rise was close to twice the size of a typical day's swing for the stock. The company said the Phase 3 trial of EDG-7500 is on track to start by year-end 2026. Phase 3 is the large, late-stage test usually needed for approval. The trial covers both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM), a thickening of the heart muscle. The company also dosed the first patient in its Phase 2 EQUINOX-HFpEF trial of a second drug, EDG-15400. What to watch next. * Whether the EDG-7500 Phase 3 trial actually starts by the end of 2026 * Enrollment updates from the EQUINOX-HFpEF trial * Next quarterly report for updated cash and spending levels Faq. What is EDG-7500? It is an experimental oral pill designed to act on the heart muscle's regulatory light chain, slowing early contraction and improving the heart's ability to relax. Positive 12-week Phase 2 results from the CIRRUS-HCM trial were presented at the European Society of Cardiology Congress in August 2026. What is EDG-15400 being tested for? It is being tested in adults with heart failure with preserved ejection fraction (HFpEF), meaning the heart pumps normally (ejection fraction of at least 50%) but relaxes poorly. The trial is listed on ClinicalTrials.gov as NCT07795814.

PR Newswire
Nov 4th, 2026
Edgewise posts $1.17B Q3 profit on $1.35B sevasemten sale gain, Phase 3 on track

Edgewise Therapeutics reported third-quarter net income of $1,166.2 million, or $9.65 per diluted share, against a net loss of $40.7 million a year earlier. The jump came from a $1.348 billion gain on selling its sevasemten program and muscular dystrophy business to Servier in July 2026. The Boulder, Colorado company received $1.396 billion in upfront cash at closing. Cash, cash equivalents and marketable securities stood at about $1,743.9 million on September 30, 2026. Research and development spending fell to $31.6 million from $37.5 million, while general and administrative costs rose to $14.6 million from $9.4 million. Edgewise expects to start a Phase 3 trial of EDG-7500 in hypertrophic cardiomyopathy by the end of 2026. It also dosed the first patient in a Phase 2 trial of EDG-15400 in heart failure with preserved ejection fraction.

Business Wire
Oct 13th, 2026
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

Recently Posted Jobs

Sign up to get curated job recommendations

Edgewise Therapeutics is Hiring for 9 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs